Cargando…

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets

AIMS: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis. METHODS AND RESULTS: The plasma proteome of 50 patients with heart failure who died or were rehospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Thong H., Jones, Donald J.L., Voors, Adriaan A., Quinn, Paulene A., Sandhu, Jatinderpal K., Chan, Daniel C.S., Parry, Helen M., Mohan, Mohapradeep, Mordi, Ify R., Sama, Iziah E., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, Hillege, Hans L., Metra, Marco, Ponikowski, Piotr, Samani, Nilesh J., Van Veldhuisen, Dirk J., Zannad, Faiez, Lang, Chim C., Ng, Leong L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028019/
https://www.ncbi.nlm.nih.gov/pubmed/31692186
http://dx.doi.org/10.1002/ejhf.1608
_version_ 1783498940484681728
author Cao, Thong H.
Jones, Donald J.L.
Voors, Adriaan A.
Quinn, Paulene A.
Sandhu, Jatinderpal K.
Chan, Daniel C.S.
Parry, Helen M.
Mohan, Mohapradeep
Mordi, Ify R.
Sama, Iziah E.
Anker, Stefan D.
Cleland, John G.
Dickstein, Kenneth
Filippatos, Gerasimos
Hillege, Hans L.
Metra, Marco
Ponikowski, Piotr
Samani, Nilesh J.
Van Veldhuisen, Dirk J.
Zannad, Faiez
Lang, Chim C.
Ng, Leong L.
author_facet Cao, Thong H.
Jones, Donald J.L.
Voors, Adriaan A.
Quinn, Paulene A.
Sandhu, Jatinderpal K.
Chan, Daniel C.S.
Parry, Helen M.
Mohan, Mohapradeep
Mordi, Ify R.
Sama, Iziah E.
Anker, Stefan D.
Cleland, John G.
Dickstein, Kenneth
Filippatos, Gerasimos
Hillege, Hans L.
Metra, Marco
Ponikowski, Piotr
Samani, Nilesh J.
Van Veldhuisen, Dirk J.
Zannad, Faiez
Lang, Chim C.
Ng, Leong L.
author_sort Cao, Thong H.
collection PubMed
description AIMS: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis. METHODS AND RESULTS: The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with 50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on two‐dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI‐MS/MS) in high definition mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up‐regulated and 46 down‐regulated with more than two‐fold expression changes in those who experienced death or rehospitalisation. Gene ontology enrichment analysis and protein–protein interaction networks of significant differentially expressed proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were rehospitalised. CONCLUSIONS: Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve poor outcomes in patients with heart failure.
format Online
Article
Text
id pubmed-7028019
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70280192020-02-25 Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets Cao, Thong H. Jones, Donald J.L. Voors, Adriaan A. Quinn, Paulene A. Sandhu, Jatinderpal K. Chan, Daniel C.S. Parry, Helen M. Mohan, Mohapradeep Mordi, Ify R. Sama, Iziah E. Anker, Stefan D. Cleland, John G. Dickstein, Kenneth Filippatos, Gerasimos Hillege, Hans L. Metra, Marco Ponikowski, Piotr Samani, Nilesh J. Van Veldhuisen, Dirk J. Zannad, Faiez Lang, Chim C. Ng, Leong L. Eur J Heart Fail Pathophysiology AIMS: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis. METHODS AND RESULTS: The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with 50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on two‐dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI‐MS/MS) in high definition mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up‐regulated and 46 down‐regulated with more than two‐fold expression changes in those who experienced death or rehospitalisation. Gene ontology enrichment analysis and protein–protein interaction networks of significant differentially expressed proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were rehospitalised. CONCLUSIONS: Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve poor outcomes in patients with heart failure. John Wiley & Sons, Ltd 2019-11-06 2020-01 /pmc/articles/PMC7028019/ /pubmed/31692186 http://dx.doi.org/10.1002/ejhf.1608 Text en © 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pathophysiology
Cao, Thong H.
Jones, Donald J.L.
Voors, Adriaan A.
Quinn, Paulene A.
Sandhu, Jatinderpal K.
Chan, Daniel C.S.
Parry, Helen M.
Mohan, Mohapradeep
Mordi, Ify R.
Sama, Iziah E.
Anker, Stefan D.
Cleland, John G.
Dickstein, Kenneth
Filippatos, Gerasimos
Hillege, Hans L.
Metra, Marco
Ponikowski, Piotr
Samani, Nilesh J.
Van Veldhuisen, Dirk J.
Zannad, Faiez
Lang, Chim C.
Ng, Leong L.
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title_full Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title_fullStr Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title_full_unstemmed Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title_short Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
title_sort plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
topic Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028019/
https://www.ncbi.nlm.nih.gov/pubmed/31692186
http://dx.doi.org/10.1002/ejhf.1608
work_keys_str_mv AT caothongh plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT jonesdonaldjl plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT voorsadriaana plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT quinnpaulenea plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT sandhujatinderpalk plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT chandanielcs plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT parryhelenm plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT mohanmohapradeep plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT mordiifyr plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT samaiziahe plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT ankerstefand plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT clelandjohng plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT dicksteinkenneth plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT filippatosgerasimos plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT hillegehansl plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT metramarco plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT ponikowskipiotr plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT samaninileshj plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT vanveldhuisendirkj plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT zannadfaiez plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT langchimc plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets
AT ngleongl plasmaproteomicapproachinpatientswithheartfailureinsightsintopathogenesisofdiseaseprogressionandpotentialnoveltreatmenttargets